QCM Cayman’s Sarepta Therapeutics SRPT Stock Holding History

QCM Cayman’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-3,218	Closed	-$425K	–	171
2018 Q2	$425K	Buy	+3,218	New	+$303K	1.97%	12

Other funds holding SRPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

QCM Cayman's SRPT Position: Q3 2018 in Review

QCM Cayman sold out of Sarepta Therapeutics (SRPT) in Q3 2018, closing a stake of 3,218 shares — an estimated $425K sold.

QCM Cayman first reported a position in SRPT in Q2 2018 and held it in 1 quarter. The position peaked at $425K in Q2 2018. 345 funds tracked by Wall St. Rank hold SRPT as of Q3 2018.

QCM Cayman reported no remaining Sarepta Therapeutics position as of Q3 2018 after selling out during the quarter.
QCM Cayman sold 3,218 Sarepta Therapeutics shares in Q3 2018, an estimated $425K.
QCM Cayman first reported a position in Sarepta Therapeutics in Q2 2018 and held it in 1 quarter.
QCM Cayman's Sarepta Therapeutics position peaked at $425K in Q2 2018.
345 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2018.

Based on QCM Cayman's 13F filing for Q3 2018, filed 14 Nov 2018.